Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Depreciation & Amortization (CF) (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $321000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 4.18% to $321000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 13.2% decrease, with the full-year FY2025 number at $1.3 million, down 13.2% from a year prior.
  • Depreciation & Amortization (CF) was $321000.0 for Q4 2025 at Akebia Therapeutics, up from $318000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $513000.0 in Q1 2021 to a low of $314000.0 in Q1 2025.
  • A 5-year average of $394850.0 and a median of $397500.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): rose 0.76% in 2024, then fell 21.0% in 2025.
  • Akebia Therapeutics' Depreciation & Amortization (CF) stood at $442000.0 in 2021, then fell by 7.69% to $408000.0 in 2022, then decreased by 3.43% to $394000.0 in 2023, then dropped by 14.97% to $335000.0 in 2024, then decreased by 4.18% to $321000.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Depreciation & Amortization (CF) are $321000.0 (Q4 2025), $318000.0 (Q3 2025), and $316000.0 (Q2 2025).